GLP-1 drugs linked to 21% lower fracture risk in type 2 diabetes patients

A large observational study from UCLA has surfaced an unexpected dimension of GLP-1 diabetes medications — drugs already celebrated for weight loss — suggesting they may also guard the aging skeleton against serious fracture. Analyzing records from nearly 134,000 adults with type 2 diabetes, researchers found a 21% reduction in fragility fractures over three years compared to a common alternative medication, with the strongest protection appearing in the hip, femur, and spine. The finding is particularly striking because it resolves a longstanding medical paradox: diabetic patients break bones